Iran’s New Coronavirus Vaccine in 2nd Stage of Clinical Phase
TEHRAN (FNA)- The home-made anti-coronavirus vaccine, Noora, has entered the second stage of clinical trials, a health official of the Islamic Revolution Guards Corps (IRGC) that is developing the vaccine said.
IRGC’s Deputy Director for Health, Medical Education and Biological Defense Affairs Brigadier General Ahmad Abdollahi the said on Monday that the second phase of the clinical trial of the recombinant Noora vaccine has started.
“We hope to make this vaccine available to the public once the second and third stages [of human trial] have been carried out,” he noted.
Noora vaccine, produced by Baqiyatallah University of Medical Sciences, was put on display during a ceremony in Tehran on June 27 in the presence of Chief Commander of the IRGC Major General Hossein Salami, Iran’s former health minister Saeed Namaki as well as other Iranian health officials.
The recombinant vaccine entered the first stage of human trial after 16 months of research work by Iranian scientists.
Its first dose was injected into the chief medial officer of Baqiyatallah Hospital Dr. Hossein Samadinia.
“It is noteworthy that a few universities in the world have been able to develop a vaccine against the virus, and it is a great honor for the Baqiyatallah University of Medical Sciences to be able to achieve this success,” Samadinia said on the sidelines of the unveiling ceremony at the time.
Meantime, on Sunday, Iran started the third phase of the human trial of its second homegrown coronavirus vaccine, Razi Cov Pars.
Razi Cov Pars is a recombinant protein subunit vaccine containing the COVID-19 spike protein. It reportedly tutors the immune system against the virus by producing antibodies.
The vaccine includes three doses. The first two doses are said to be injectable, whilst the third dose is intranasal.
The second dose of the vaccine will be injected into volunteers 21 days after the first inoculation, and the third dose will be inhaled 51 days later.
Iran has also successfully completed the first phase of the human trial for FAKHRAVAC COVID-19 vaccine developed by the Organization of Defensive Innovation and Research.
FAKHRAVAC is an inactivated virus-based vaccine, and apparently requires two doses given by intramuscular injection 14 days apart.